UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Genetic testing for gynaecological cancer

Gaba, FM; Manchanda, R; (2017) Genetic testing for gynaecological cancer. Obstetrics, Gynaecology & Reproductive Medicine , 27 (1) pp. 29-31. 10.1016/j.ogrm.2016.11.001. Green open access

[thumbnail of OGRM_genetic testing gynae cancer_v9.pdf]
OGRM_genetic testing gynae cancer_v9.pdf - Accepted Version

Download (174kB) | Preview


The traditional family-history approach to genetic testing involves taking a detailed three generation family-history from both sides of the family, ethnicity, type of cancer, age of onset and death. Testing for BRCA1/BRCA2 mutations is offered at a ≥10% combined BRCA1/BRCA2 probability. Risk models such as the Manchester scoring system, BOADICEA and BRCAPRO can be used to calculate BRCA1/BRCA2 probability. High-risk women identified should be referred to a regional genetics service for genetic counselling and testing. The Amsterdam-Criteria-2 have been traditionally used to identify Lynch syndrome (caused by a mismatch repair gene (MLH1/MSH2/MSH6/PMS2) mutation). Molecular (immunohistochemistry and Microsatellite instability) analysis of tumour tissue is now established as an initial step, with genetic testing undertaken for protein deficient or MSI unstable tumours. This is offered for those fulfilling Bethesda criteria and recently for all colorectal cancer cases <60 years. BRCA1/BRCA2 testing is recommended for all non-mucinous invasive epithelial ovarian cancers irrespective of family-history (10–20% have a BRCA1/BRCA2 mutation). This is being undertaken by non-genetics clinicians. A population-based approach to genetic testing identifies 50% more carriers at risk. It has been extensively investigated in the Ashkenazi-Jewish population and found to be extremely cost-effective in this community. This is expected to lead to change in guidelines in the future.

Type: Article
Title: Genetic testing for gynaecological cancer
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ogrm.2016.11.001
Publisher version: http://dx.doi.org/10.1016/j.ogrm.2016.11.001
Language: English
Additional information: Copyright © 2016 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: BRCA; breast cancer; endometrial cancer; genetic testing; high risk; Lynch syndrome; ovarian cancer; risk prediction
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
URI: https://discovery.ucl.ac.uk/id/eprint/1536089
Downloads since deposit
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item